Sabine Wilhelm1,2, Katharine A Phillips3,4,5,6, Jennifer L Greenberg1,2, Sheila M O'Keefe1,2, Susanne S Hoeppner1,2, Aparna Keshaviah7, Suraj Sarvode-Mothi1, David A Schoenfeld2,8. 1. Department of Psychiatry, Massachusetts General Hospital, Boston. 2. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. 3. Department of Psychiatry, Rhode Island Hospital, Providence. 4. Department of Psychiatry, New York-Presbyterian Hospital, New York. 5. Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island. 6. Department of Psychiatry, Weill Cornell Medical College, New York, New York. 7. Mathematica Policy Research, Cambridge, Massachusetts. 8. Department of Biostatistics, Massachusetts General Hospital, Boston.
Abstract
Importance: Cognitive behavioral therapy (CBT), the best-studied treatment for body dysmorphic disorder (BDD), has to date not been compared with therapist-delivered supportive psychotherapy, the most commonly received psychosocial treatment for BDD. Objective: To determine whether CBT for BDD (CBT-BDD) is superior to supportive psychotherapy in reducing BDD symptom severity and associated BDD-related insight, depressive symptoms, functional impairment, and quality of life, and whether these effects are durable. Design, Setting, and Participants: This randomized clinical trial conducted at Massachusetts General Hospital and Rhode Island Hospital recruited adults with BDD between October 24, 2011, and July 7, 2016. Participants (n = 120) were randomized to the CBT-BDD arm (n = 61) or the supportive psychotherapy arm (n = 59). Weekly treatments were administered at either hospital for 24 weeks, followed by 3- and 6-month follow-up assessments. Measures were administered by blinded independent raters. Intention-to-treat statistical analyses were performed from February 9, 2017, to September 22, 2018. Interventions: Cognitive behavioral therapy for BDD, a modular skills-based treatment, addresses the unique symptoms of the disorder. Supportive psychotherapy is a nondirective therapy that emphasizes the therapeutic relationship and self-esteem; supportive psychotherapy was enhanced with BDD-specific psychoeducation and treatment rationale. Main Outcomes and Measures: The primary outcome was BDD symptom severity measured by the change in score on the Yale-Brown Obsessive-Compulsive Scale Modified for BDD from baseline to end of treatment. Secondary outcomes were the associated symptoms and these were assessed using the Brown Assessment of Beliefs Scale, Beck Depression Inventory-Second Edition, Sheehan Disability Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. Results: Of the 120 participants, 92 (76.7%) were women, with a mean (SD) age of 34.0 (13.1) years. The difference in effectiveness between CBT-BDD and supportive psychotherapy was site specific: at 1 site, no difference was detected (estimated mean [SE] slopes, -18.6 [1.9] vs -16.7 [1.9]; P = .48; d growth-modeling analysis change, -0.25), whereas at the other site, CBT-BDD led to greater reductions in BDD symptom severity, compared with supportive psychotherapy (estimated mean [SE] slopes, -18.6 [2.2] vs -7.6 [2.0]; P < .001; d growth-modeling analysis change, -1.36). No posttreatment symptom changes were observed throughout the 6 -months of follow-up (all slope P ≥ .10). Conclusions and Relevance: Body dysmorphic disorder severity and associated symptoms appeared to improve with both CBT-BDD and supportive psychotherapy, although CBT-BDD was associated with more consistent improvement in symptom severity and quality of life. Trial Registration: ClinicalTrials.gov identifier: NCT01453439.
RCT Entities:
Importance: Cognitive behavioral therapy (CBT), the best-studied treatment for body dysmorphic disorder (BDD), has to date not been compared with therapist-delivered supportive psychotherapy, the most commonly received psychosocial treatment for BDD. Objective: To determine whether CBT for BDD (CBT-BDD) is superior to supportive psychotherapy in reducing BDD symptom severity and associated BDD-related insight, depressive symptoms, functional impairment, and quality of life, and whether these effects are durable. Design, Setting, and Participants: This randomized clinical trial conducted at Massachusetts General Hospital and Rhode Island Hospital recruited adults with BDD between October 24, 2011, and July 7, 2016. Participants (n = 120) were randomized to the CBT-BDD arm (n = 61) or the supportive psychotherapy arm (n = 59). Weekly treatments were administered at either hospital for 24 weeks, followed by 3- and 6-month follow-up assessments. Measures were administered by blinded independent raters. Intention-to-treat statistical analyses were performed from February 9, 2017, to September 22, 2018. Interventions: Cognitive behavioral therapy for BDD, a modular skills-based treatment, addresses the unique symptoms of the disorder. Supportive psychotherapy is a nondirective therapy that emphasizes the therapeutic relationship and self-esteem; supportive psychotherapy was enhanced with BDD-specific psychoeducation and treatment rationale. Main Outcomes and Measures: The primary outcome was BDD symptom severity measured by the change in score on the Yale-Brown Obsessive-Compulsive Scale Modified for BDD from baseline to end of treatment. Secondary outcomes were the associated symptoms and these were assessed using the Brown Assessment of Beliefs Scale, Beck Depression Inventory-Second Edition, Sheehan Disability Scale, and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. Results: Of the 120 participants, 92 (76.7%) were women, with a mean (SD) age of 34.0 (13.1) years. The difference in effectiveness between CBT-BDD and supportive psychotherapy was site specific: at 1 site, no difference was detected (estimated mean [SE] slopes, -18.6 [1.9] vs -16.7 [1.9]; P = .48; d growth-modeling analysis change, -0.25), whereas at the other site, CBT-BDD led to greater reductions in BDD symptom severity, compared with supportive psychotherapy (estimated mean [SE] slopes, -18.6 [2.2] vs -7.6 [2.0]; P < .001; d growth-modeling analysis change, -1.36). No posttreatment symptom changes were observed throughout the 6 -months of follow-up (all slope P ≥ .10). Conclusions and Relevance: Body dysmorphic disorder severity and associated symptoms appeared to improve with both CBT-BDD and supportive psychotherapy, although CBT-BDD was associated with more consistent improvement in symptom severity and quality of life. Trial Registration: ClinicalTrials.gov identifier: NCT01453439.
Authors: T Deckersbach; C R Savage; K A Phillips; S Wilhelm; U Buhlmann; S L Rauch; L Baer; M A Jenike Journal: J Int Neuropsychol Soc Date: 2000-09 Impact factor: 2.892
Authors: Brett J Deacon; Nicholas R Farrell; Joshua J Kemp; Laura J Dixon; Jennifer T Sy; Annie R Zhang; Patrick B McGrath Journal: J Anxiety Disord Date: 2013-05-04
Authors: Jennifer L Greenberg; Nicholas C Jacobson; Susanne S Hoeppner; Emily E Bernstein; Ivar Snorrason; Anna Schwartzberg; Gail Steketee; Katharine A Phillips; Sabine Wilhelm Journal: J Psychiatr Res Date: 2022-06-08 Impact factor: 5.250
Authors: Berta J Summers; Susanne S Hoeppner; Clare C Beatty; Mark A Blais; Jennifer L Greenberg; Katharine A Phillips; Sabine Wilhelm Journal: Behav Ther Date: 2021-12-24
Authors: Katharine A Phillips; Jennifer L Greenberg; Susanne S Hoeppner; Hilary Weingarden; Sheila O'Keefe; Aparna Keshaviah; David A Schoenfeld; Sabine Wilhelm Journal: J Affect Disord Date: 2021-03-11 Impact factor: 4.839
Authors: Hilary Weingarden; Susanne S Hoeppner; Ivar Snorrason; Jennifer L Greenberg; Katharine A Phillips; Sabine Wilhelm Journal: Depress Anxiety Date: 2021-03-16 Impact factor: 8.128
Authors: Jorge Valderrama; Stella Kim Hansen; Carlos Pato; Katharine Phillips; James Knowles; Michele T Pato Journal: Psychiatry Res Date: 2020-05-06 Impact factor: 11.225
Authors: Hilary Weingarden; Aleksandar Matic; Roger Garriga Calleja; Jennifer L Greenberg; Oliver Harrison; Sabine Wilhelm Journal: JMIR Mhealth Uhealth Date: 2020-06-18 Impact factor: 4.773